The 90% Effective Dose of Remimazolam for Duodenoscopy Insertion During ERCP With Alfentanil 10µg/kg
Primary Purpose
Anesthesia
Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Remimazolam
Sponsored by

About this trial
This is an interventional treatment trial for Anesthesia focused on measuring ERCP, remimazolam, alfentanil, ED90
Eligibility Criteria
Inclusion Criteria:
- Age is between 18 and 85 years
- ASA I-III levels;
- Patients undergone elective ERCP surgery, non-intubation patients;
Exclusion Criteria:
- Chronic pain with long-term use of analgesics, psychotropic substances (including opioids, NSAIDs, sedatives, antidepressants), alcohol abusers, with known drug allergy;
- BMI<18 or BMI>30;
- Previous abnormal surgical anesthesia recovery history;
- Hypertension or systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 95 mmHg when the patient admission to the operating room
- Suffering from esophageal reflux; • Sedatives, analgesics and antipruritic drugs were used 24 hours before operation;
- Expected difficult intubation ;
- Opioids allergy history;
- Take monoamine oxidase inhibitor or antidepressant within 15 days;
- Pregnant or parturient women;
- Involved in other drug trials within three months;
- Patients who can not communicate well with the researcher
Sites / Locations
- Tianjin Nankai HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
Other
Arm Label
Experimental: age<65 group
Active Comparator:age ≥65 group
Arm Description
The 90% effective dose of remimazolam for duodenoscopy insertion with alfentanil 10µg/kg
The 90% effective dose of remimazolam for duodenoscopy insertion with alfentanil 10µg/kg
Outcomes
Primary Outcome Measures
The number of success duodenoscopy insertion
success duodenoscopy insertion is defined by no body movement
Secondary Outcome Measures
The number of the occurrence of hypotension
hypotension is defined MAP decrease by 20%
The number of the occurrence of bradycardia
bradycardia is defined lower than 50 beats / min
The number of the occurrence of injection pain
injection pain is defined the patient complained of vascular pain
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05053763
Brief Title
The 90% Effective Dose of Remimazolam for Duodenoscopy Insertion During ERCP With Alfentanil 10µg/kg
Official Title
The 90% Effective Dose of Remimazolam for Duodenoscopy Insertion During ERCP
Study Type
Interventional
2. Study Status
Record Verification Date
December 2021
Overall Recruitment Status
Recruiting
Study Start Date
September 22, 2021 (Actual)
Primary Completion Date
December 25, 2022 (Anticipated)
Study Completion Date
December 25, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Jianbo Yu
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Remimazolam has shown promising results for sedation in colonoscopy . Alfentanil is widely used in the analgesia of ERCP . The purpose of the study was to determine the 90% Effective Dose of Remimazolam for Duodenoscopy Insertion During ERCP With Alfentanil 10µg/kg
Detailed Description
1. Title:The 90% Effective Dose of Remimazolam for Duodenoscopy Insertion During ERCP With Alfentanil 10µg/kg 2. Research center: Single center. 3. The population of the study: Age is between 18 and 85 years; ASA I-III levels; Patients undergone elective ERCP surgery, non-intubation patients; 4. Sample size:The sample size was decided based on that of prior Literature.The study was carried out using a biased coin design up-and-down sequential method, where the dose of remimazolam administered to each patient depended on the response of the previous one with success/failure duodenoscopy insertion during ERCP are required for reliable estimates. The first patient recruited received a dose of 0.2mg/kg, based on our past experience.Subsequently, if a patient had a failure duodenoscopy insertion, the dose of remimazolam was increased by 0.025mg/kg in the next subject. If a patient had a successful duodenoscopy insertion the next subject was randomised to receive either a lower dose (with a decrement of 0.025mg/kg), with a probability of b = 0.11, or the same dose, with a probability of 1-b = 0.89.
We defined duodenoscopy insertion a failure was as gross purposeful muscular movement, coughing or vomiting occurring during or within 2 minutes of insertion of duodenoscopy. If BIS>75 and MOAA/S > 1 when 3 min after the intravenous injection of remimazolam, it was considered a failure, and the patient received rescue sedation. Success was depicted when the reactions mentioned earlier were absent.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anesthesia
Keywords
ERCP, remimazolam, alfentanil, ED90
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Non-Randomized
Enrollment
120 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Experimental: age<65 group
Arm Type
Other
Arm Description
The 90% effective dose of remimazolam for duodenoscopy insertion with alfentanil 10µg/kg
Arm Title
Active Comparator:age ≥65 group
Arm Type
Other
Arm Description
The 90% effective dose of remimazolam for duodenoscopy insertion with alfentanil 10µg/kg
Intervention Type
Drug
Intervention Name(s)
Remimazolam
Intervention Description
The study was carried out using a biased coin design up-and-down sequential method, where the dose of remimazolam administered to each patient depended on the response of the previous one with success/failure duodenoscopy insertion during ERCP are required for reliable estimates. The first patient was tested at 0.2mg/kg remimazolam (0.025mg/kg as a step size). Duodenoscopy insertion was conducted when MOAA/S≤1.The response of the patients to the duodenoscopy insertion during ERCP was categorized as either 'success (no movement)' or 'failure (movement). if a patient had a failure duodenoscopy insertion, the dose of remimazolam was increased by 0.025mg/kg in the next subject. If a patient had a successful duodenoscopy insertion the next subject was randomised to receive either a lower dose (with a decrement of 0.025mg/kg), with a probability of b = 0.11, or the same dose, with a probability of 1-b = 0.89.
Primary Outcome Measure Information:
Title
The number of success duodenoscopy insertion
Description
success duodenoscopy insertion is defined by no body movement
Time Frame
1 day
Secondary Outcome Measure Information:
Title
The number of the occurrence of hypotension
Description
hypotension is defined MAP decrease by 20%
Time Frame
1 day
Title
The number of the occurrence of bradycardia
Description
bradycardia is defined lower than 50 beats / min
Time Frame
1 day
Title
The number of the occurrence of injection pain
Description
injection pain is defined the patient complained of vascular pain
Time Frame
1 day
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age is between 18 and 85 years
ASA I-III levels;
Patients undergone elective ERCP surgery, non-intubation patients;
Exclusion Criteria:
Chronic pain with long-term use of analgesics, psychotropic substances (including opioids, NSAIDs, sedatives, antidepressants), alcohol abusers, with known drug allergy;
BMI<18 or BMI>30;
Previous abnormal surgical anesthesia recovery history;
Hypertension or systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 95 mmHg when the patient admission to the operating room
Suffering from esophageal reflux; • Sedatives, analgesics and antipruritic drugs were used 24 hours before operation;
Expected difficult intubation ;
Opioids allergy history;
Take monoamine oxidase inhibitor or antidepressant within 15 days;
Pregnant or parturient women;
Involved in other drug trials within three months;
Patients who can not communicate well with the researcher
Facility Information:
Facility Name
Tianjin Nankai Hospital
City
Tianjin
State/Province
Tianjin
ZIP/Postal Code
300000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yu Jianbo, Professor
Phone
(022)27435008
Ext
(022)27435027
Email
yujianbo11@126.com
12. IPD Sharing Statement
Learn more about this trial
The 90% Effective Dose of Remimazolam for Duodenoscopy Insertion During ERCP With Alfentanil 10µg/kg
We'll reach out to this number within 24 hrs